Molecular therapy in a model neuroendocrine disease: Developing clinical gene therapy for pituitary tumours

Trends in Endocrinology and Metabolism

Volumn 12, Issue 2, 2001, Pages 58-64

  Castro, Maria G ^a   Southgate, Thomas ^a   Lowenstein, Pedro R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; ANIMAL; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS 1; HUMAN; HYPOPHYSIS TUMOR; MULTIMODALITY CANCER THERAPY; RETROVIRUS; REVIEW;

ADENOVIRIDAE; ANIMALS; COMBINED MODALITY THERAPY; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; PITUITARY NEOPLASMS; RETROVIRIDAE;

EID: 0035289941     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(00)00358-1     Document Type: Review

References (56)

1. Stone, D. et al. (2000) Viral vectors for gene delivery and therapy in the endocrine system. J. Endocrinol. 164, 103-118
2. Human gene marker/therapy clinical protocols (complete updated listings) (1999) Hum. Gene Ther. 10, 3067-3123
3. Cavazzana, C. et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672
4. Naldini, L. et al. (1997) Efficient transfer, integration, and sustained long term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U. S. A. 93, 11382-11388
5. Naldini, L. et al. (1998) Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol. 9, 457-463
6. Feng, M. et al. (1997) Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat. Biotechnol. 15, 866-870
7. Duisit, G. et al. (1999) Functional characterization of adenoviral/retroviral producer cell lines. Hum. Gene Ther. 20, 189-200
8. Constantini, L.C. et al. (1999) Gene transfer to the nigrostriatal system by hybrid herpes simplex virus amplicon vectors. Hum. Gene Ther. 10, 2481-2494
9. Johnston, K.M. et al. (1997) HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther. 8, 359-370
10. Yang, Y. et al. (1996) Transient immune blockade prevents formation of neutralizing antibody adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3, 412-420
11. Byrnes, A.P. et al. (1996) Immunological instability of persistent adenovirus vectors in the brain. Peripheral exposure to vector leads to renewed inflammation, reduced gene expression and demyelination. J. Neurosci. 16, 3045-3055
12. Molnar-Kimber, K.L. et al. (1998) Impact of preexisting and induced humoral and cellular immune response to gene therapy phase 1 clinical trial for localized mesothelioma. Hum. Gene Ther. 9, 2121-2133
13. Chirmule, N. et al. (2000) Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol. 74, 2420-2425
14. Chen, P. et al. (2000) Effective repeat administration with adenovirus vectors to the muscle. Gene Ther. 7, 587-595
15. Kemp, L.M. et al. (1990) Transcriptional repression of herpes simplex virus immediate-early genes and of octamer containing cellular promoters in neuronal cells is mediated by the octamer DNA element. Neuron 4, 215-222
16. Akli, S. et al. (1993) Transfer of a foreign gene into the brain using adenovirus vectors. Nat. Genet. 3, 224-228
17. Lowenstein, P.R. et al. (1994) Use of recombinant vectors derived from herpes simplex virus 1 mutant tsK for short-term expression of transgenes encoding cytoplasmic and membrane anchored proteins in postmitotic polarized cortical neurons and glial cells in vitro. Neuroscience 60, 1059-1077
18. Castro, M.G. et al. (1997) Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: long term expression, cell cycle dependency, and effects on hormone secretion. Endocrinology 138, 2184-2194
19. Geddes, B.J. et al. (1997) Long-term gene therapy in the CNS: reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nat. Med. 3, 1402-1404
20. Goya, R. et al. (1998) Use of recombinant herpes simplex virus type 1 vectors for gene transfer into tumour and normal anterior pituitary cells. Mol. Cell. Endocrinol. 138, 199-207
21. Dewey R.A. et al. (1999) Chronic brain inflammation and persistent HSV1-TK expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat. Med. 5, 1256-1263
22. Lo, W.D. et al. (1999) Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum. Gene Ther. 10, 201-213
23. Kotin, RM. and Berns, K.I. (1989) Organisation of adeno-associated virus DNA in latency infected Detroit 6 cells. Virology 170, 460-467
24. Murphy, J.E. et al. (1997) Long-term correction of obesity and diabetes in genetically obese mice by a single injection of recombinant adeno-associated virus encoding mouse leptin. Proc. Natl. Acad Sci. U. S. A. 94, 13921-13926
25. Southgate, T.D. et al. (2001) Long-term transgene expression within the anterior pituitary gland in situ: impact on circulating hormone levels, cellular and antibody-mediated immune responses. Endocrinology 142, 464-476
26. Thomas, C.E. et al. (2000) Peripheral infection with adenovirus causes unexpected long term brain inflammation in animals injected intracranially with first generation, but not with high-capacity adenovirus vectors: towards realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. U. S. A. 97, 7482-7487
27. Gossen, M. and Bujard, H. (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad Sci. U. S. A. 89, 5547-5551
28. Rivera, V.M. et al. (1996) A humanized system for pharmacologic control of gene expression. Nat. Med. 2, 21028-21032
29. Harding, T.C. et al. (1998) Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat. Biotechnol. 16, 553-555
30. Corti, O. et al. (1999) A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors. Nat. Biotechnol. 17, 349-354
31. Smith-Arica, J. et al. (2000) Cell type specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression. Mol. Ther. 2, 579-587
32. Southgate, T.D. et al. (2000) Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride induced hyperplastic anterior pituitaries. Endocrinology 141, 3493-3505
33. Thomas, C. et al. (2001) Acute direct adenoviral vector cytotoxicity, and chronic, but not acute inflammatory responses correlate with decreased vector mediated transgene expression in the brain. Mol. Ther. 3. 36-46
34. Windeatt, S. et al. (2000) Adenovirus-mediated HSV-1 thymidine kinase gene therapy suppressed oestrogen induced pituitary prolactinomas. J. Clin. Endocrinol. Metab. 85, 1296-1306
35. Lowenstein, P.R. (1997) Why are we doing so much cancer gene therapy? Disentangling the scientific basis from the origins of gene therapy. Gene Ther. 4, 755-756
36. Pellegrini, I. et al. (1989) Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab. 69, 500-509
37. Caccavilli, L. et al. (1994) Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60, 314-322
38. Colao, A. et al. (1997) Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline therapy. J. Clin. Endocrinol. Metab. 82, 876-883
39. Wilson, C.B. (1997) Extensive surgical experience. Surgical management of pituitary tumors. J. Clin. Endocrinol. Metab. 82, 2381-2385
40. Tyrrell, J.B. et al. (1999) Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long term results. Neurosurgery 44, 254-263
41. Girkin, C.A. et al. (1997) Radiation optic neuropathy after stereotactic radiosurgery Ophthalmology 104, 1634-1643
42. Tsang, R.W. et al. (1993) Glioma arising after radiation therapy for pituitary adenoma. Cancer 72, 2227-2233
43. Jones, A. (1991) Radiation oncogenesis in relation to the treatment of pituitary tumours. Clin. Endocrinol. 35, 379-397
44. Chiocca, E.A. (1998) Experimental and clinical gene therapies for brain tumours. In Gene Therapy for Neurological Disorders and Brain Tumours (Chiocca, E.A. and Breakefield, X.O., eds), pp. 191-203, Humana Press
45. Lowenstein, P.R. et al. (1999) The basic science of brain-tumour gene therapy. Biochem. Soc. Trans. 27, 873-881
46. Castleden, S.A. et al. (1997) Afamily of bicistronic vectors to enhance both local and systemic antitumour effects of HSVtk or cytokine expression in a murine melanoma model. Hum. Gene Ther. 8, 2087-2102
47. Kuriyama, S. et al. (1999) Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated responses and causes apoptotic death or tumour cells in vivo. Int. J. Cancer 83, 374-380
48. Lee, E.J. et al. (1999) Targeted expression of toxic genes directed by pituitary hormone promoters: a potential strategy for adenovirus-mediated gene therapy of pituitary tumors. J. Clin. Endocrinol. Metab. 84, 786-794
49. Lee, E.J. et al. (2000) Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: implications for gene therapy. Neurosurgery 46, 1461-1468
50. Levy, A. (1999) Mitosis and apoptosis in the pituitary gland: tumour formation or hyperplasia? In Bailliere's Best Practise and Research in Endocrinology and Metabolism (Vol. 13) (Holly, J.M.P., ed.), pp. 353-365, Harcourt Brace
51. Khuri, F.R. et al. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885
52. O'Reilly, M.S. et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328
53. O'Reilly, M.S. et al. (1996) Angiostatin induces and sustains dormancy of human primary tumours in mice. Nat. Med. 2, 689-692
54. Wickham, T.J. (2000) Targeting adenovirus. Gene Ther. 7, 110-114
55. Blaese, R.M. et al. (2000) T lymphocyte-directed gene therapy for ADA-SCID: initial results after 4 years. Science 270, 475-480
56. Friedmann, T. and Roblin, R. (1972) Gene therapy for human genetic disease? Science 175, 949-955